Cargando…
Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
BACKGROUND: Patient engagement and patient-centered care are critical in optimally managing patients with end-stage renal disease (ESRD). Understanding patient preferences is a key element of patient-centered care and shared decision making. The objective of this study was to elicit patients’ prefer...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532768/ https://www.ncbi.nlm.nih.gov/pubmed/28750605 http://dx.doi.org/10.1186/s12882-017-0665-8 |
_version_ | 1783253519604645888 |
---|---|
author | Hauber, Brett Caloyeras, John Posner, Joshua Brommage, Deborah Belozeroff, Vasily Cooper, Kerry |
author_facet | Hauber, Brett Caloyeras, John Posner, Joshua Brommage, Deborah Belozeroff, Vasily Cooper, Kerry |
author_sort | Hauber, Brett |
collection | PubMed |
description | BACKGROUND: Patient engagement and patient-centered care are critical in optimally managing patients with end-stage renal disease (ESRD). Understanding patient preferences is a key element of patient-centered care and shared decision making. The objective of this study was to elicit patients’ preferences for the treatment of secondary hyperparathyroidism (SHPT) associated with ESRD using a discrete-choice experiment survey. METHODS: Clinical literature, nephrologist input, patient-education resources, and a patient focus group informed development of the survey instrument, which was qualitatively pretested before its administration to a broader sample of patients. The National Kidney Foundation invited individuals in the United States with ESRD who were undergoing hemodialysis to participate in the survey. Respondents chose among three hypothetical SHPT treatment alternatives (two medical alternatives and surgery) in each of a series of questions, which were defined by attributes of efficacy (effect on laboratory values and symptoms), safety, tolerability, mode of administration, and cost. The survey instrument included a best-worst scaling exercise to quantify the relative bother of the individual attributes of surgery. Random-parameters logit models were used to evaluate the conditional relative importance of the attributes. RESULTS: A total of 200 patients with ESRD completed the survey. The treatment attributes that were most important to the respondents were whether a treatment was a medication or surgery and out-of-pocket cost. Patients had statistically significant preferences for efficacy attributes related to symptom management and laboratory values, but placed less importance on the attributes related to mode of administration and side effects. The most bothersome attribute of surgery was the risk of surgical mortality. CONCLUSIONS: Patients with ESRD and SHPT who are undergoing hemodialysis understand SHPT and have clear and measurable treatment preferences. These results may help inform clinicians about patients’ preferences regarding treatment options for a common complication of ESRD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-017-0665-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5532768 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55327682017-08-02 Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism Hauber, Brett Caloyeras, John Posner, Joshua Brommage, Deborah Belozeroff, Vasily Cooper, Kerry BMC Nephrol Research Article BACKGROUND: Patient engagement and patient-centered care are critical in optimally managing patients with end-stage renal disease (ESRD). Understanding patient preferences is a key element of patient-centered care and shared decision making. The objective of this study was to elicit patients’ preferences for the treatment of secondary hyperparathyroidism (SHPT) associated with ESRD using a discrete-choice experiment survey. METHODS: Clinical literature, nephrologist input, patient-education resources, and a patient focus group informed development of the survey instrument, which was qualitatively pretested before its administration to a broader sample of patients. The National Kidney Foundation invited individuals in the United States with ESRD who were undergoing hemodialysis to participate in the survey. Respondents chose among three hypothetical SHPT treatment alternatives (two medical alternatives and surgery) in each of a series of questions, which were defined by attributes of efficacy (effect on laboratory values and symptoms), safety, tolerability, mode of administration, and cost. The survey instrument included a best-worst scaling exercise to quantify the relative bother of the individual attributes of surgery. Random-parameters logit models were used to evaluate the conditional relative importance of the attributes. RESULTS: A total of 200 patients with ESRD completed the survey. The treatment attributes that were most important to the respondents were whether a treatment was a medication or surgery and out-of-pocket cost. Patients had statistically significant preferences for efficacy attributes related to symptom management and laboratory values, but placed less importance on the attributes related to mode of administration and side effects. The most bothersome attribute of surgery was the risk of surgical mortality. CONCLUSIONS: Patients with ESRD and SHPT who are undergoing hemodialysis understand SHPT and have clear and measurable treatment preferences. These results may help inform clinicians about patients’ preferences regarding treatment options for a common complication of ESRD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-017-0665-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-07-28 /pmc/articles/PMC5532768/ /pubmed/28750605 http://dx.doi.org/10.1186/s12882-017-0665-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Hauber, Brett Caloyeras, John Posner, Joshua Brommage, Deborah Belozeroff, Vasily Cooper, Kerry Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism |
title | Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism |
title_full | Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism |
title_fullStr | Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism |
title_full_unstemmed | Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism |
title_short | Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism |
title_sort | hemodialysis patients’ preferences for the management of secondary hyperparathyroidism |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532768/ https://www.ncbi.nlm.nih.gov/pubmed/28750605 http://dx.doi.org/10.1186/s12882-017-0665-8 |
work_keys_str_mv | AT hauberbrett hemodialysispatientspreferencesforthemanagementofsecondaryhyperparathyroidism AT caloyerasjohn hemodialysispatientspreferencesforthemanagementofsecondaryhyperparathyroidism AT posnerjoshua hemodialysispatientspreferencesforthemanagementofsecondaryhyperparathyroidism AT brommagedeborah hemodialysispatientspreferencesforthemanagementofsecondaryhyperparathyroidism AT belozeroffvasily hemodialysispatientspreferencesforthemanagementofsecondaryhyperparathyroidism AT cooperkerry hemodialysispatientspreferencesforthemanagementofsecondaryhyperparathyroidism |